Post by
themagicbox on Mar 31, 2022 12:53pm
Otena still in the game
On a more productive note, I found a very interesting drug for rheumatoid arthritis called baricitinib. Its getting traction in the news because of Jada smiths alopacia indicdent. https://en.wikipedia.org/wiki/Baricitinib
Anyway, this Eli lily drug got rejected by the FDA in April 2017 for "concerns about dosing and safety" but was approved a year later.
And in 2020 the FDA granted it "breakthrough therapy" designation to baricitinib for the treatment of alopecia.
When I reviewed the concenrs for dosing and safety, it was a some serious stuff. Hardly comparable to the Otenas elevated ALTs. Food for thought.
I am looking forward to seeing what happens with Otena in the next 2 years.
Comment by
woundedknee on Mar 31, 2022 3:24pm
This is all fine if you are a 30 or 40 year shareholder. I don't even think Dan will live long enough to see this a post op pain killer. lol
Comment by
MrMugsy on Mar 31, 2022 4:17pm
Dan just wants to see it going to P3 without liver confusion - then he can sell it. Hope we can get the dosing right going into P2 - much easier than with chronic (you'd think). Also - would be really good to have chronic figured out by the time we negotiate. Hoping a much higher dose and less frequency (less than daily) will do the trick !!! Fingers crossed that it all comes together.